The pathophysiology of benign prostatic hyperplasia

Drugs of Today

Volumn 38, Issue 12, 2002, Pages 867-876

  Djavan, Bob ^a   Remzi, Mesut ^a   Erne, Beate ^a   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANDROSTANOLONE; ANTIBIOTIC AGENT; CANDICIDIN; ESTROGEN; FINASTERIDE; HYPOCHOLESTEROLEMIC AGENT; PLANT EXTRACT; SOMATOMEDIN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA;

AGING; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; HYPERPLASIA; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; REVIEW;

AGING; ANDROGENS; APOPTOSIS; EPITHELIAL CELLS; ESTROGENS; GROWTH SUBSTANCES; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; STEM CELLS; STROMAL CELLS;

EID: 0036998947     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2002.38.12.740205     Document Type: Review

References (50)

1. Napalkov, P., Maisonneuve, P., Boyle, P. Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 1995, 46(Suppl. 3A): 41-6.
2. Barry, M.J., Cockett, A.T.K., Holtgrewe, H.L. et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993, 150: 351-8.
3. Yalla, S.V., Sullivan, M.P, Lecamwasam, H.S. et al. Correlation of American Urologic Association Symptom Index with obstructive and nonobstructive prostatism. J Urol 1995, 153: 674-80.
4. Jacobsen, S.J., Girman, C.J., Lieber, M.M. Natural history of benign prostatic hyperplasia. Urology 2001, 58(Suppl. 6A): 5-16.
5. Arrighi, H.M., Metter, E.J., Guess, H.A., Fozzard, J.D. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 1991, 38(Suppl. 1): 4-8.
6. Girman, C.J., Panser, L.A., Chute, C.G. et al. Natural history of prostatism: Urinary flow rates in a community-based study. J Urol 1993, 150: 887-92.
7. Diokno, A.C., Brown, M.B., Goldstein, N.G. et al. Urinary flow rates and voiding pressures in elderly men living in a community. J Urol 1994, 151: 1550-3.
8. McConnell, J.D., Barry, M.J., Bruskewitz, R.C. et al. Benign prostatic hyperplasia: Diagnosis and treatment. Clinical Practice Guidelines, Number 8. AHCPR Publication No. 94-0582. Rockville, MD, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services 1994.
9. McNeal, J.E. Normal histology of the prostate. Am J Surg Path 1988, 12: 619-33.
10. Berry, S.J., Coffey, D.S., Walsh, P.C. The development of human benign prostatic hyperplasia with age. J Urol 1984, 132: 474-9.
11. Guess, H.A., Arrighi, H.M., Metter, E.J., Fozard, J.L. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990, 17: 241-6.
12. Lee, C., Kozlowski, J., Grayhack, J. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 1997, 31: 2131-8.
13. Bartsch, G., Rittmaster, R.S., Klocker, H. Dihydrotestosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000, 37: 367-80.
14. Pelletier, G., Luu-The, V., Huang, X.F. et al. Localization by in situ hybridization of steroid 5alpha-reductase isoenzyme gene expression in the human prostate and preputial skin. J Urol 1998, 160:577-82.
15. Rittmaster, R.S. 5alpha-reductase inhibitors. J Androl 1997, 18: 582-7.
16. Steers, W.D. 5alpha-reductase activity in the prostate. Urology 2001, 58(Suppl. 6A): 17-24.
17. Reyes, E.M., Camacho-Arroyo, I., Nava, G. et al. Differential methylation in steroid 5alpha-reducrase isoenzymes genes in epididymis, testis, and liver of the adult rat. J Androl 1997, 18: 372-7.
18. Marks, L.S., Partin, A.W., Dorey, F.J. et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999, 53: 574-80.
19. Harper, M., Glynn Jones, E., Goddard, L. et al. Expression of androgen receptor and growth factors in pre-malignant lesions of the prostate. J Path 1998, 186:169-77.
20. Cunha, G.R. The role of androgens in the epithelial-mesenchymal interactions involved in prostatic morphogenesis in embryonic mice. Anat Rec 1973, 175:87-96.
21. Cunha, G., Battle, E., Young, P. et al. Role of epithelial-mesenchymal interactions in the differentiation and spatial organisation of visceral smooth muscle. Epith Cell Biol 1992, 1: 76-83.
22. Lee, C., Kozlowski, J.M., Grayhack, J.T. Intrinsic and extrinsic factor controlling benign prostatic growth. Prostate 1997, 31: 131-8.
23. Fransworth, W.E. Estrogen in the etiopathogenesis of BPH. Prostate 1999, 41: 263-74.
24. Walsh, P.C., Wilson, J.D. The induction of prostatic hypertrophy in the dog with androstendiol. J Clin Invest 1976, 57:1093-7
25. Winter, M.L., Liehr, J.G. Possible mechanism of induction of benign prostatic hyperplasia by estradiol and dihydrotestosterone in dogs. Toxicol Appl Pharmacol 1996, 136: 211-9.
26. Brendler, C.B., Berry, S.J., Ewing, L.L. et al. Spontaneous benign prostatic hyperplasia in the beagle. Age-associated changes in serum hormone levels, and the morphology and secretory function of the canine prostate. J Clin Invest 1983, 71: 114-23.
27. Coffey, D.S., Walsh, P.C. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990, 17: 461-75
28. Isaacs, J.T., McDermott, I.R., Coffey, D.S. The identification and characterization of the C1903 steroid metabolites of 5 alpha-androstane-3 beta, 17 beta-diol produced by the canine prostate: 5 alpha-androstane-3 beta, 6 alpha, 17 beta-triol and 5 alpha-androstane-3 beta, 7 alpha, 17 beta-triol. Steroids 1980, 35: 139-56.
29. Prins, G.S., Marmer, M., Woodham, C. et al. Estrogen receptor-beta messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology 1998, 139:874-83.
30. Isaacs, J.T., Coffey, D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989,2: 33-50.
31. Kamischke, A., Weinbauer, G.F., Semjonow, A. et al. Estradiol and high-dose testosterone treatment causes changes in cynomolgus monkey prostate volume and histology identical to those caused by testosterone alone. J Androl 1999, 20: 601-10.
32. Montironi, R., Valli, M., Fabris, G. Treatment of benign prostatic hyperplasia with 5alpha-reductase inhibitor: Morphological changes in patients who fail to respond. J Clin Pathol 1996, 49: 324-8.
33. Mydlo, J.H, Michaeli, J., Heston, W.D.W., Fair, W.R. Expression of basic fibroblast growth factor mRNA in benign prostatic hyperplasia and prostatic carcinoma. Prostate 1988, 13: 241-7.
34. Gann, P.H., Chatterton, R., Vogelsong, K. et al. Epidermal growth factor-related peptides in human prostatic fluid: Source of variability in assay results. Prostate 1997, 32: 234-40.
35. Jones, J.I., Clemmonds, D.R. Insulin-like growth factors and their binding proteins. Biological actions. Endocr Rev 1995, 16: 3-34.
36. Madison, L., Webb, N.R., Rose, T.M TM. et al. Transforming growth factor-beta 2: cDNA cloning and sequence analysis. DNA 1988, 7: 1-8.
37. Hofer, D., Sherwood, E.R., Bromberg, W. et al. Autonomous growth of androgen-independent prostatic carcinoma cells. Role of TGF-alpha. Cancer Res 1991, 51: 2780-5.
38. Abraham, J.A., Whang, J.L., Tumolo, A. et al. Human basic fibroblast growth factor. Nucleotide sequence and genomic organization. EMBO J 1986, 5:2525-8.
39. Stukowski, D.M., Fong, C.J., Sensibar, J.A. et al. Interaction of epidermal growth factor and transforming growth factor-beta 1 in human prostatic epithelial cells in culture. Prostate 1992, 21: 133-43.
40. Ilio, K.Y, Park, I., Lee, C. Apoptotic activity of doxazosin is mediated through an autocrine expression of TGF-beta. Prostate 2001, 48: 131-5.
41. Steiner, M.S. Role of peptide growth factors in the prostate. A review. Urology 1993, 42: 99-110.
42. Foster, B.A., Cunha, C.R. Efficacy of various natural and synthetic androgens to induce ductal branching morphogenesis in the developing anterior rat prostate. Endocrinology 1999, 140: 318-28.
43. Kryprianou, N., Litvak, J.P., Borkowski, A. et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998, 159: 1810-5.
44. Chon, J.K., Borkowski, A., Partin, A. et al. Alpha1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999, 161: 2002-8.
45. Glassman, D.T., Chon, J.K., Borkowski, A. et al. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 2001, 46: 45-51.
46. Lepor, H., Williford, W.O., Barry, M.L. et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996, 335: 533-9.
47. Djavan, B., Nickel, J.C., de la Rosette, J., Abrams, P. The urologists view of BPH progression: Results of an international survey. Eur Urol 2002, 41: 490-6.
48. Djavan, B., Marberger, M. A meta-analysis in the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999, 36: 1-13.
49. Djavan, B. Transurethral microwave thermotherapy. Tech Urol 2000, 6: 243-4.
50. Djavan, B. Guidelines on benign prostatic hyperplasia: Where do we stand in the new millennium? Curr Urol Rep 2002, 3: 91-2.